The ethics of talking about ‘HIV cure’

BMC Medical Ethics

Keymanthri Moodley⁴  Joseph D Tucker²  Mark Siedner¹  Stuart Rennie³ 

[1] Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA;UNC Project-China, Guangdong Provincial Dermatology/STD Hospital, Guangzhou, China;Center for Bioethics, Department of Social Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA;Center for Medical Ethics and Law, Department of Medicine, Stellenbosch University, Tygerberg, South Africa

关键词: Biomedical research;    HIV cure;    Ethics;    HIV/AIDS;   

Others  :  1144801
DOI  :  10.1186/s12910-015-0013-0

 received in 2014-09-04, accepted in 2015-03-09,  发布年份 2015

【 摘 要 】

Background

In 2008, researchers reported that Timothy Brown (the ‘Berlin Patient’), a man with HIV infection and leukemia, received a stem-cell transplant that removed HIV from his body as far as can be detected. In 2013, an infant born with HIV infection received anti-retroviral treatment shortly after birth, but was then lost to the health care system for the next six months. When tested for HIV upon return, the child (the ‘Mississippi Baby’) had no detectable viral load despite cessation of treatment. These remarkable clinical developments have helped reinvigorate the field of ‘HIV cure’ research.

Discussion

Although this research field is largely in a pre-clinical phase, talk about curing HIV has become a regular feature in the global mass media. This paper explores the language of HIV cure from philosophical, ethical and historical perspectives. Examination of currently influential definitions of ‘functional’ and ‘sterilizing’ HIV cure reveal that these conceptualizations are more complicated than they seem. Cure is often understood in narrowly biomedical terms in isolation from the social and psychological dimensions of illness. Contemporary notions of HIV cure also inherit some of the epistemic problems traditionally associated with cures for other health conditions, such as cancer. Efforts to gain greater conceptual clarity about cure lead to the normative question of how ‘HIV cure research’ ought to be talked about.

Summary

We argue that attention to basic concepts ethically matter in this context, and identify advantages as well as potential pitfalls of how different HIV/AIDS stakeholders may make use of the concept of cure. While concepts other than cure (such as remission) may be appropriate in clinical contexts, use of the word cure may be justified for other important purposes in the struggle against HIV/AIDS.

【 授权许可】

   
2015 Rennie et al.; licensee BioMed Central.

【 参考文献 】

• [1]Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al.: Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009, 360:692-8.
• [2]McNeil DG (2013) Marrow transplants fail to cure two H.I.V. patients. The New York Times, December 6, 2013, Page A13.
• [3]Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al.: Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013, 9:e1003211.
• [4]Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M Jr, Chun TW, et al.: Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013, 369:1828-35.
• [5]“Mississippi Baby” now has detectable HIV, researchers find.” NIH News, July 10, 2014 [http://www.niaid.nih.gov/news/newsreleases/2014/Pages/MississippiBabyHIV.aspx].
• [6]Raw Story/Agence-Press France. Early HIV treatment has second U.S. baby disease-free within a year. March 5, 2014. [http://www.cnn.com/2014/03/06/health/hiv-baby-cured/].
• [7]Bitnun A, Samson L, Chun TW, Kakkar F, Brophy J, Murray D et. al. Early Initiation of Combination Antiretroviral Therapy in HIV-1-Infected Newborns Can Achieve Sustained Virologic Suppression With Low Frequency of CD4+ T Cells Carrying HIV in Peripheral Blood. Clin Infect Dis. 2014, Jun 9. pii: ciu432. [Epub ahead of print].
• [8]CTV News. May 3, 2014. HIV resurfaces in Canadian child after break in drug treatment. Available at: http://www.ctvnews.ca/health/hiv-resurfaces-in-canadian-child-after-break-in-drug-treatment-1.1804770#ixzz3BttfaO9D.
• [9]Deacon BJ: The biomedical model of mental disorder: a critical analysis of its validity, utility and effects on psychotherapy research. Clin Psychol Rev 2013, 33:846-61.
• [10]Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al.: Role of viral replication, antiretroviral therapy and Immunodeficiency in HIV-associated atherosclerosis. AIDS 2009, 23(9):1059-67.
• [11]FDA (2013) HIV patient-focused drug development backgrounder document. [http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM354549.pdf]
• [12]Churchill M. Towards an HIV cure. Global Scientific Strategy. 1st Stakeholders consultation meeting, 28 September 2011. Available at: http://iasociety.org/Web/WebContent/File/HIV_Cure_Churchill_Canberra_Presentation.pdf.
• [13]Miller K, Abraham JH, Rhodes L, Roberts R: Use of the word ‘cure’ in oncology. J Oncol Practice 2013, 9:e136-40.
• [14]Engel GL: The need for a new medical model: a challenge for biomedicine. Science 1977, 196:129-36.
• [15]Wilson SJ, Bladin PF, Saling MM: Paradoxical results in the cure of chronic illness: the ‘burden of normality’ as exemplified following seizure surgery. Epilepsy Behav 2004, 5:13-21.
• [16]Mullan F: Seasons of survival: reflections of a physician with cancer. NEJM 1985, 313:270-3.
• [17]Van Eys J: The truly cured child. Pediatrician 1991, 18:90-5.
• [18]Hilton P, Robinson D: Defining cure. Neurourol Urodyn 2011, 30:741-5.
• [19]Easson EC, Russell MH: Cure of Hodgkin’s disease. BMJ 1963, 5347:1704-7.
• [20]Chen JY: Can we use the ‘C’ word with confidence? Cure for chronic hepatitis C. Gastroenterology 2011, 140:766-8.
• [21]Hamilton HE, Gordon C, Nelson M, Cotler SJ, Martin P: How physicians describe outcomes to HCV therapy: prevalence and meaning of ‘cure’ during provider-patient in-office discussions of HCV. J Clin Gastroenterol 2008, 42:419-24.
• [22]Katlama C, Deeks SG, Autran B, Martinez-Picado J, Van L, Rouzioux C, et al.: Barriers to a cure for HIV: new ways to target and eradicate HIV reservoirs. Lancet 2013, 381:2109-17.
• [23]Theilman NM, Osterman J, Whetten K, Whetten R, Itemba D, Maro V, et al.: Reduced adherence to antiretroviral therapy among HIV-infected Tanzanians seeking cure from the Lonliondo healer. JAIDS 2014, 65:e104-9. The authors conclude: “Recognizing and addressing the lure of alternative cures for HIV infection and their impact on adherence is critical to the continued success of HIV care and treatment programs in resource-poor settings
• [24]Henderson GE, Easter MM, Zimmer C, King NMP, Davis AM, Rothschild BB, et al.: Therapeutic misconception in early phase gene transfer trials. Soc Sci Med 2006, 62:239-53.
• [25]Dube K, Henderson GE, Margolis DM: Framing expectations in early HIV cure research. Trends in Microbiology: Science & Society 2004, 10:547-549.
• [26]Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA, et al.: Antiretroviral refusal among newly diagnosed HIV-infected adults. AIDS 2011, 25(17):2177-81.
• [27]Kennedy C, O’Reilly K, Medley A, Sweat M: The impact of HIV treatment on risk behavior in developing countries: a systematic review. AIDS Care 2007, 19:707-20.
• [28]Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Tae-Wook C, et al.: HIV persistence and the prospect of long-term drug-free remission for HIV infected individuals. Science 2010, 329:174-80.
• [29]Tucker JD, Volberding PA, Margolis DM, Rennie S, Barre-Sinoussi F: Words Matter: Discussing Research Towards an HIV Cure in Research and Clinical Contexts. JAIDS 2014, 3:e110-1.